Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
Tinsay A. Woreta(Johns Hopkins University), Arun J. Sanyal(Virginia Commonwealth University), Manal F. Abdelmalek(Mayo Clinic), Emily Mitchell(Johns Hopkins University), David E. Kleiner, Norah A. Terrault(University of California, San Francisco), Samer Gawrieh(Indiana University School of Medicine), Anna Mae Diehl(Duke University), Raj Vuppalanchi(Virginia Commonwealth University), Mariana Lazo(Johns Hopkins University), Mark Fishbein(Northwestern University), Rohit Loomba(University of California San Diego), Mark L. Van Natta(Johns Hopkins University), Arthur J. McCullough(Case Western Reserve University), Cynthia Behling(Johns Hopkins University), Jeanne M. Clark(Johns Hopkins University), Paula M. Hertel(Baylor College of Medicine), Brent A. Neuschwander‐Tetri(Saint Louis University), Laura Wilson(Johns Hopkins University), Arunkumar Krishnan(Levine Cancer Institute), Naga Chalasani(Indiana University School of Medicine), Kris V. Kowdley(Washington State University Spokane), Laura Miriel(Johns Hopkins University), Mohammad Shadab Siddiqui(Virginia Commonwealth University), James Tonascia(Johns Hopkins University), Srinivasan Dasarathy(Cleveland Clinic)
Cited by 43
Related Papers
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
|Hepatology|2017|7.2k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k